Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Moderate Buy” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $6.5714.

A number of equities research analysts have commented on NMRA shares. Needham & Company LLC reduced their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Friday, July 17th. Wall Street Zen cut shares of Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada decreased their target price on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth approximately $27,000. HBK Sorce Advisory LLC acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at $26,000. Virtu Financial LLC acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at $31,000. Fred Alger Management LLC bought a new stake in Neumora Therapeutics during the 4th quarter valued at $40,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Neumora Therapeutics during the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $1.64 on Friday. The company has a market cap of $303.86 million, a price-to-earnings ratio of -1.23 and a beta of 2.75. Neumora Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.65. The company has a quick ratio of 5.09, a current ratio of 5.09 and a debt-to-equity ratio of 0.75. The firm has a 50 day moving average of $1.62 and a 200-day moving average of $2.14.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, equities analysts forecast that Neumora Therapeutics will post -0.93 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.